SHC

INSIDER SELL

Sotera Health Co

Research: Finviz ↗·Perplexity ↗

No convergence signal this quarter — shown because tracked funds have filed 13D/G on this stock.

Days to cover (short int.)

6.8d↑+20.2%

as of 2026-09-30

News Summary

Positive

Sotera Health reported a strong Q2 2026 earnings beat with 9.2% revenue growth and raised full-year 2026 guidance to $1.236–$1.254 billion (5.25–6.75% constant-currency growth), driving a 5.9% stock rally on August 6, 2026. A planned CEO transition was completed in late May with Alton Shader (ex-Viant Medical) assuming the CEO role while founder Michael Petras moved to Executive Chairman, and analyst sentiment improved with Citi upgrading to Buy.

Insider Activity

Name	Title	Type	Shares	Price	Value	Filed	Src
Petras Michael B. Jr.	Executive Chairman	SELL	295K	$18.50	$5.45M	2026-08-17	↗
Petras Michael B. Jr.	Executive Chairman	SELL	850K	$18.50	$15.73M	2026-08-17	↗
Rutz Michael P	President of Sterigenics	SELL	150K	$18.84	$2.83M	2026-08-07	↗

Fund 13D/13G Filings (2)

Tracked funds' beneficial-ownership filings on this stock — disclosed within days of a position change, fresher than the quarterly 13F. Since Filing compares the stock to SPY from the filing date (shown for filings within the last 90 days).

Fund	Form	∆ Shares	% of Class	Since Filing	Filed	Src
Sachem Head Capital	SC 13G/A	−15.6M	0.0%	+0.6% vs SPY +0.5% abs	2026-10-09	↗
Sachem Head Capital	SC 13G	NEW	5.5%	+19.1% vs SPY +24.6% abs	2026-05-15	↗